Risperidone-induced extrapyramidal reactions. 1995

T Mahmood, and E B Clothier, and R Bridgman

UI MeSH Term Description Entries
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001480 Basal Ganglia Diseases Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA. Extrapyramidal Disorders,Basal Ganglia Disorders,Lenticulostriate Disorders,Basal Ganglia Disease,Basal Ganglia Disorder,Extrapyramidal Disorder,Lenticulostriate Disorder
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D018492 Dopamine Antagonists Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. Dopamine Antagonist,Dopamine Blocker,Dopamine Receptor Antagonist,Dopamine Receptor Antagonists,Dopaminergic Antagonist,Dopaminergic Antagonists,Antagonists, Dopamine,Antagonists, Dopamine Receptor,Antagonists, Dopaminergic,Dopamine Blockers,Antagonist, Dopamine,Antagonist, Dopamine Receptor,Antagonist, Dopaminergic,Blocker, Dopamine,Blockers, Dopamine,Receptor Antagonist, Dopamine,Receptor Antagonists, Dopamine
D018967 Risperidone A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA. R-64,766,R-64766,Risperdal Consta,Risperidal,Consta, Risperdal,R 64,766,R 64766,R64,766,R64766

Related Publications

T Mahmood, and E B Clothier, and R Bridgman
January 1963, Acta neurologica Scandinavica. Supplementum,
T Mahmood, and E B Clothier, and R Bridgman
February 2002, Journal of paediatrics and child health,
T Mahmood, and E B Clothier, and R Bridgman
March 1977, The New England journal of medicine,
T Mahmood, and E B Clothier, and R Bridgman
January 2000, International journal of psychiatry in clinical practice,
T Mahmood, and E B Clothier, and R Bridgman
May 1987, Neurology,
T Mahmood, and E B Clothier, and R Bridgman
September 1984, Medicina clinica,
T Mahmood, and E B Clothier, and R Bridgman
March 1961, JAMA,
T Mahmood, and E B Clothier, and R Bridgman
December 1973, Archives of neurology,
T Mahmood, and E B Clothier, and R Bridgman
January 1983, Clinical neuropharmacology,
T Mahmood, and E B Clothier, and R Bridgman
April 2004, The American journal of psychiatry,
Copied contents to your clipboard!